Last updated on February 2018

Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gastrointestinal Hemorrhage | Esophageal Varices | Fibrosis | Cirrhosis
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • 18 y.o. age75 y.o.;
  • Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N-butyl-cyanoacrylate injection).

Exclusion Criteria:

  • age <18 y.o. or age > 75 y.o.;
  • Never had the variceal bleeding episode before;
  • Do not have endoscopic treatment;
  • combined with other malignant tumor (not exclude patients with hepatocellular carcinoma who don't not need treatment at the moment);
  • Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)
  • Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics.
  • Acute variceal bleeding within 5 days.
  • Use of other antibiotics in the past 2 weeks;
  • Refuse to participate

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.